Your session is about to expire
← Back to Search
Cirmtuzumab Consolidation for Chronic Lymphocytic Leukemia (Venetoclax Trial)
Venetoclax Trial Summary
This trial is testing whether a drug called cirmtuzumab can help people with cancer who have responded to treatment with venetoclax.
Venetoclax Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowVenetoclax Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Venetoclax Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I stopped taking venetoclax over 6 months ago and my cancer is considered low risk.My blood test shows more than 0.01% leukemia cells.I am currently taking venetoclax.I have been on venetoclax for at least 12 months.I am currently taking venetoclax.
- Group 1: Cirmtuzumab + Venetoclax
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are recruitment efforts for this research ongoing at this time?
"That is accurate. The clinicaltrials.gov website has information indicating that this trial is actively recruiting patients. This specific study was first advertised on August 6th 2020 and updated November 24th 2021. Currently, the trial is looking for 16 individuals across 1 medical site."
What are the odds of developing negative side effects from Cirmtuzumab?
"Cirmtuzumab falls into a Phase 2 category, which suggests that while there is data attesting to its safety, none has been collected regarding the medication's efficacy. Our team at Power rated it as a 2."
Are there any similar past clinical trials that utilized Cirmtuzumab?
"Cirmtuzumab is being studied in 226 active clinical trials, 29 of which are Phase 3 studies. Most of the research on Cirmtuzumab is taking place in Boston, but there are 7269 total locations running trials for this medication."
How many participants are being included in this research project?
"Yes, the trial is still accepting patients. According to the website, clinicaltrials.gov, the study was first posted on 8/6/2020 and updated as recently as 11/24/2021. Currently, they are looking for 16 more participants at 1 site."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Most responsive sites:
- UCSD Koman Family Outpatient Pavilion: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger